Enhanced tumor delivery and antitumor response of doxorubicin loaded albumin nanoparticles formulated based on a Schiff base

Fang Li,1,2,* Chunli Zheng,1,* Junbo Xin,2 Fangcheng Chen,1 Hua Ling,3 Linlin Sun,4 Thomas J Webster,4,5 Xin Ming,6 Jianping Liu1 1School of Pharmacy, China Pharmaceutical University, Nanjing, 2School of Pharmacy, Yancheng Vocational Institute of Health Sciences, Yancheng, People’s Republi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li F, Zheng C, Xin J, Chen F, Ling H, Sun L, Webster TJ, Ming X, Liu J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	doxorubicin albumin nanoparticles Schiff base tumor delivery anticancer response Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/ba669ff6f7c84335bf46ae752aae6acc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ba669ff6f7c84335bf46ae752aae6acc
record_format	dspace
spelling	oai:doaj.org-article:ba669ff6f7c84335bf46ae752aae6acc2021-12-02T05:40:43ZEnhanced tumor delivery and antitumor response of doxorubicin loaded albumin nanoparticles formulated based on a Schiff base1178-2013https://doaj.org/article/ba669ff6f7c84335bf46ae752aae6acc2016-08-01T00:00:00Zhttps://www.dovepress.com/enhanced-tumor-delivery-and-antitumor-response-of-doxorubicin-loaded-a-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Fang Li,1,2,* Chunli Zheng,1,* Junbo Xin,2 Fangcheng Chen,1 Hua Ling,3 Linlin Sun,4 Thomas J Webster,4,5 Xin Ming,6 Jianping Liu1 1School of Pharmacy, China Pharmaceutical University, Nanjing, 2School of Pharmacy, Yancheng Vocational Institute of Health Sciences, Yancheng, People’s Republic of China; 3School of Pharmacy, Hampton University, Hampton, VA, 4Department of Chemical Engineering, Northeastern University, Boston, MA, USA; 5Center of Excellence for Advanced Materials Research, King Abdulaziz University, Jeddah, Saudi Arabia; 6Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA *These authors contributed equally to this work Abstract: A novel method was developed here to prepare albumin-based nanoparticles (NPs) for improving the therapeutic and safety profiles of chemotherapeutic agents. This approach involved crosslinking bovine serum albumin (BSA) using a Schiff base-containing vanillin, into NPs and loading doxorubicin (DOX) into the NPs by incubation. The resultant NPs (DOX-BSA-V-NPs) displayed a particle size of 100.5±1.3 nm with a zeta potential of –23.05±1.45 mV and also showed high drug-loading efficiency and excellent stability with respect to storage and temperature. The encapsulation of DOX into the BSA-V-NPs was confirmed by dynamic scanning calorimetry and Raman spectroscopy. DOX-BSA-V-NPs exhibited a significantly faster DOX release at pH 6.5 than pH 7.4, as well as in a solution with a higher glutathione concentration. In vitro studies showed that the cellular uptake of DOX-BSA-V-NPs was time-dependent, concentration-dependent, and faster than free DOX, while the cytotoxicity of DOX-BSA-V-NPs (IC50 value of 3.693 µg/mL) was superior to free DOX (IC50 value of 4.007 µg/mL). More importantly, DOX-BSA-V-NPs showed a longer mean survival time of 24.83 days, a higher tumor inhibition rate of 56.66%, and a decreased distribution in the heart than other DOX formulations in animal studies using a tumor xenograft model. Thus, the vanillin-based albumin NPs were shown here to be a promising carrier for tumor-targeted delivery of chemotherapeutic agents and, thus, should be further studied. Keywords: doxorubicin, albumin nanoparticles, Schiff base, tumor delivery, anticancer responseLi FZheng CXin JChen FLing HSun LWebster TJMing XLiu JDove Medical Pressarticledoxorubicinalbumin nanoparticlesSchiff basetumor deliveryanticancer responseMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 11, Pp 3875-3890 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	doxorubicin albumin nanoparticles Schiff base tumor delivery anticancer response Medicine (General) R5-920
spellingShingle	doxorubicin albumin nanoparticles Schiff base tumor delivery anticancer response Medicine (General) R5-920 Li F Zheng C Xin J Chen F Ling H Sun L Webster TJ Ming X Liu J Enhanced tumor delivery and antitumor response of doxorubicin loaded albumin nanoparticles formulated based on a Schiff base
description	Fang Li,1,2,* Chunli Zheng,1,* Junbo Xin,2 Fangcheng Chen,1 Hua Ling,3 Linlin Sun,4 Thomas J Webster,4,5 Xin Ming,6 Jianping Liu1 1School of Pharmacy, China Pharmaceutical University, Nanjing, 2School of Pharmacy, Yancheng Vocational Institute of Health Sciences, Yancheng, People’s Republic of China; 3School of Pharmacy, Hampton University, Hampton, VA, 4Department of Chemical Engineering, Northeastern University, Boston, MA, USA; 5Center of Excellence for Advanced Materials Research, King Abdulaziz University, Jeddah, Saudi Arabia; 6Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA *These authors contributed equally to this work Abstract: A novel method was developed here to prepare albumin-based nanoparticles (NPs) for improving the therapeutic and safety profiles of chemotherapeutic agents. This approach involved crosslinking bovine serum albumin (BSA) using a Schiff base-containing vanillin, into NPs and loading doxorubicin (DOX) into the NPs by incubation. The resultant NPs (DOX-BSA-V-NPs) displayed a particle size of 100.5±1.3 nm with a zeta potential of –23.05±1.45 mV and also showed high drug-loading efficiency and excellent stability with respect to storage and temperature. The encapsulation of DOX into the BSA-V-NPs was confirmed by dynamic scanning calorimetry and Raman spectroscopy. DOX-BSA-V-NPs exhibited a significantly faster DOX release at pH 6.5 than pH 7.4, as well as in a solution with a higher glutathione concentration. In vitro studies showed that the cellular uptake of DOX-BSA-V-NPs was time-dependent, concentration-dependent, and faster than free DOX, while the cytotoxicity of DOX-BSA-V-NPs (IC50 value of 3.693 µg/mL) was superior to free DOX (IC50 value of 4.007 µg/mL). More importantly, DOX-BSA-V-NPs showed a longer mean survival time of 24.83 days, a higher tumor inhibition rate of 56.66%, and a decreased distribution in the heart than other DOX formulations in animal studies using a tumor xenograft model. Thus, the vanillin-based albumin NPs were shown here to be a promising carrier for tumor-targeted delivery of chemotherapeutic agents and, thus, should be further studied. Keywords: doxorubicin, albumin nanoparticles, Schiff base, tumor delivery, anticancer response
format	article
author	Li F Zheng C Xin J Chen F Ling H Sun L Webster TJ Ming X Liu J
author_facet	Li F Zheng C Xin J Chen F Ling H Sun L Webster TJ Ming X Liu J
author_sort	Li F
title	Enhanced tumor delivery and antitumor response of doxorubicin loaded albumin nanoparticles formulated based on a Schiff base
title_short	Enhanced tumor delivery and antitumor response of doxorubicin loaded albumin nanoparticles formulated based on a Schiff base
title_full	Enhanced tumor delivery and antitumor response of doxorubicin loaded albumin nanoparticles formulated based on a Schiff base
title_fullStr	Enhanced tumor delivery and antitumor response of doxorubicin loaded albumin nanoparticles formulated based on a Schiff base
title_full_unstemmed	Enhanced tumor delivery and antitumor response of doxorubicin loaded albumin nanoparticles formulated based on a Schiff base
title_sort	enhanced tumor delivery and antitumor response of doxorubicin loaded albumin nanoparticles formulated based on a schiff base
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/ba669ff6f7c84335bf46ae752aae6acc
work_keys_str_mv	AT lif enhancedtumordeliveryandantitumorresponseofdoxorubicinloadedalbuminnanoparticlesformulatedbasedonaschiffbase AT zhengc enhancedtumordeliveryandantitumorresponseofdoxorubicinloadedalbuminnanoparticlesformulatedbasedonaschiffbase AT xinj enhancedtumordeliveryandantitumorresponseofdoxorubicinloadedalbuminnanoparticlesformulatedbasedonaschiffbase AT chenf enhancedtumordeliveryandantitumorresponseofdoxorubicinloadedalbuminnanoparticlesformulatedbasedonaschiffbase AT lingh enhancedtumordeliveryandantitumorresponseofdoxorubicinloadedalbuminnanoparticlesformulatedbasedonaschiffbase AT sunl enhancedtumordeliveryandantitumorresponseofdoxorubicinloadedalbuminnanoparticlesformulatedbasedonaschiffbase AT webstertj enhancedtumordeliveryandantitumorresponseofdoxorubicinloadedalbuminnanoparticlesformulatedbasedonaschiffbase AT mingx enhancedtumordeliveryandantitumorresponseofdoxorubicinloadedalbuminnanoparticlesformulatedbasedonaschiffbase AT liuj enhancedtumordeliveryandantitumorresponseofdoxorubicinloadedalbuminnanoparticlesformulatedbasedonaschiffbase
_version_	1718400318753996800

Enhanced tumor delivery and antitumor response of doxorubicin loaded albumin nanoparticles formulated based on a Schiff base

Ejemplares similares